25 results on '"Considine C"'
Search Results
2. Broadband enhancement of light-matter interaction in 2D semiconductors by photonic hypercrystals
- Author
-
Galfsky, T., primary, Sun, Z., additional, Considine, C. R., additional, Lee, Y. H., additional, Narimanov, E. E., additional, and Menon, V. M., additional
- Published
- 2016
- Full Text
- View/download PDF
3. Grand Rounds
- Author
-
Fayolle, G., primary, Levick, W., additional, Lajiness-O'Neill, R., additional, Fastenau, P., additional, Briskin, S., additional, Bass, N., additional, Silva, M., additional, Critchfield, E., additional, Nakase-Richardson, R., additional, Hertza, J., additional, Loughan, A., additional, Perna, R., additional, Northington, S., additional, Boyd, S., additional, Anderson, A., additional, Peery, S., additional, Chafetz, M., additional, Maris, M., additional, Ramezani, A., additional, Sylvester, C., additional, Goldberg, K., additional, Constantinou, M., additional, Karekla, M., additional, Hall, J., additional, Edwards, M., additional, Balldin, V., additional, Strutt, A., additional, Pavlik, V., additional, Marquez de la Plata, C., additional, Cullum, M., additional, lacritz, l., additional, Reisch, J., additional, Massman, P., additional, Royall, D., additional, Barber, R., additional, Younes, S., additional, Wiechmann, A., additional, O'Bryant, S., additional, Patel, K., additional, Suhr, J., additional, Chari, S., additional, Yokoyama, J., additional, Bettcher, B., additional, Karydas, A., additional, Miller, B., additional, Kramer, J., additional, Zec, R., additional, Fritz, S., additional, Kohlrus, S., additional, Robbs, R., additional, Ala, T., additional, Gifford, K., additional, Cantwell, N., additional, Romano, R., additional, Jefferson, A., additional, Holland, A., additional, Newton, S., additional, Bunting, J., additional, Coe, M., additional, Carmona, J., additional, Harrison, D., additional, Puente, A., additional, Terry, D., additional, Faraco, C., additional, Brown, C., additional, Patel, A., additional, Watts, A., additional, Kent, A., additional, Siegel, J., additional, Miller, S., additional, Ernst, W., additional, Chelune, G., additional, Holdnack, J., additional, Sheehan, J., additional, Duff, K., additional, Pedraza, O., additional, Crawford, J., additional, Miller, L., additional, Hobson Balldin, V., additional, Benavides, H., additional, Johnson, L., additional, Tshuma, L., additional, Dezhkam, N., additional, Hayes, L., additional, Love, C., additional, Stephens, B., additional, Webbe, F., additional, Mulligan, K., additional, Dunham, K., additional, Shadi, S., additional, Sofko, C., additional, Denney, R., additional, Rolin, S., additional, Sibson, J., additional, Ogbeide, S., additional, Glover, M., additional, Warchol, A., additional, Hunter, B., additional, Nichols, C., additional, Riccio, C., additional, Cohen, M., additional, Dennison, A., additional, Wasserman, T., additional, Schleicher-Dilks, S., additional, Adler, M., additional, Golden, C., additional, Olivier, T., additional, LeMonda, B., additional, McGinley, J., additional, Pritchett, A., additional, Chang, L., additional, Cloak, C., additional, Cunningham, E., additional, Lohaugen, G., additional, Skranes, J., additional, Ernst, T., additional, Parke, E., additional, Thaler, N., additional, Etcoff, L., additional, Allen, D., additional, Andrews, P., additional, McGregor, S., additional, Daniels, R., additional, Hochsztein, N., additional, Miles-Mason, E., additional, Granader, Y., additional, Vasserman, M., additional, MacAllister, W., additional, Casto, B., additional, Patrick, K., additional, Hurewitz, F., additional, Chute, D., additional, Booth, A., additional, Koch, C., additional, Roid, G., additional, Balkema, N., additional, Kiefel, J., additional, Bell, L., additional, Maerlender, A., additional, Belkin, T., additional, Katzenstein, J., additional, Semerjian, C., additional, Culotta, V., additional, Band, E., additional, Yosick, R., additional, Burns, T., additional, Arenivas, A., additional, Bearden, D., additional, Olson, K., additional, Jacobson, K., additional, Ubogy, S., additional, Sterling, C., additional, Taub, E., additional, Griffin, A., additional, Rickards, T., additional, Uswatte, G., additional, Davis, D., additional, Sweeney, K., additional, Llorente, A., additional, Boettcher, A., additional, Hill, B., additional, Ploetz, D., additional, Kline, J., additional, Rohling, M., additional, O'Jile, J., additional, Holler, K., additional, Petrauskas, V., additional, Long, J., additional, Casey, J., additional, Duda, T., additional, Hodsman, S., additional, Stricker, S., additional, Martner, S., additional, Hansen, R., additional, Ferraro, F., additional, Tangen, R., additional, Hanratty, A., additional, Tanabe, M., additional, O'Callaghan, E., additional, Houskamp, B., additional, McDonald, L., additional, Pick, L., additional, Guardino, D., additional, Pietz, T., additional, Kayser, K., additional, Gray, R., additional, Letteri, A., additional, Crisologo, A., additional, Witkin, G., additional, Sanders, J., additional, Mrazik, M., additional, Harley, A., additional, Phoong, M., additional, Melville, T., additional, La, D., additional, Gomez, R., additional, Berthelson, L., additional, Robbins, J., additional, Lane, E., additional, Rahman, P., additional, Konopka, L., additional, Fasfous, A., additional, Zink, D., additional, Peralta-Ramirez, N., additional, Perez-Garcia, M., additional, Su, S., additional, Lin, G., additional, Kiely, T., additional, Schatzberg, A., additional, Keller, J., additional, Dykstra, J., additional, Feigon, M., additional, Renteria, L., additional, Fong, M., additional, Piper, L., additional, Lee, E., additional, Vordenberg, J., additional, Contardo, C., additional, Magnuson, S., additional, Doninger, N., additional, Luton, L., additional, Drane, D., additional, Phelan, A., additional, Stricker, W., additional, Poreh, A., additional, Wolkenberg, F., additional, Spira, J., additional, DeRight, J., additional, Jorgensen, R., additional, Fitzpatrick, L., additional, Crowe, S., additional, Woods, S., additional, Doyle, K., additional, Weber, E., additional, Cameron, M., additional, Cattie, J., additional, Cushman, C., additional, Grant, I., additional, Blackstone, K., additional, Moore, D., additional, Roberg, B., additional, Somogie, M., additional, Thelen, J., additional, Lovelace, C., additional, Bruce, J., additional, Gerstenecker, A., additional, Mast, B., additional, Litvan, I., additional, Hargrave, D., additional, Schroeder, R., additional, Buddin, W., additional, Baade, L., additional, Heinrichs, R., additional, Boseck, J., additional, Berry, K., additional, Koehn, E., additional, Davis, A., additional, Meyer, B., additional, Gelder, B., additional, Sussman, Z., additional, Espe-Pfeifer, P., additional, Musso, M., additional, Barker, A., additional, Jones, G., additional, Gouvier, W., additional, Johnson, V., additional, Zaytsev, L., additional, Freier-Randall, M., additional, Sutton, G., additional, Ringdahl, E., additional, Olsen, J., additional, Byrd, D., additional, Rivera-Mindt, M., additional, Fellows, R., additional, Morgello, S., additional, Wheaton, V., additional, Jaehnert, S., additional, Ellis, C., additional, Olavarria, H., additional, Loftis, J., additional, Huckans, M., additional, Pimental, P., additional, Frawley, J., additional, Welch, M., additional, Jennette, K., additional, Rinehardt, E., additional, Schoenberg, M., additional, Strober, L., additional, Genova, H., additional, Wylie, G., additional, DeLuca, J., additional, Chiaravalloti, N., additional, Ibrahim, E., additional, Seiam, A., additional, Bohlega, S., additional, Lloyd, H., additional, Goldberg, M., additional, Marceaux, J., additional, Fallows, R., additional, McCoy, K., additional, Yehyawi, N., additional, Luther, E., additional, Hilsabeck, R., additional, Fulton, R., additional, Stevens, P., additional, Erickson, S., additional, Dodzik, P., additional, Williams, R., additional, Dsurney, J., additional, Najafizadeh, L., additional, McGovern, J., additional, Chowdhry, F., additional, Acevedo, A., additional, Bakhtiar, A., additional, Karamzadeh, N., additional, Amyot, F., additional, Gandjbakhche, A., additional, Haddad, M., additional, Johnson, M., additional, Wade, J., additional, Harper, L., additional, Barghi, A., additional, Mark, V., additional, Christopher, G., additional, Marcus, D., additional, Spady, M., additional, Bloom, J., additional, Zimmer, A., additional, Miller, M., additional, Schuster, D., additional, Ebner, H., additional, Mortimer, B., additional, Palmer, G., additional, Happe, M., additional, Paxson, J., additional, Jurek, B., additional, Graca, J., additional, Meyers, J., additional, Lange, R., additional, Brickell, T., additional, French, L., additional, Iverson, G., additional, Shewchuk, J., additional, Madler, B., additional, Heran, M., additional, Brubacher, J., additional, Ivins, B., additional, Baldassarre, M., additional, Paper, T., additional, Herrold, A., additional, Chin, A., additional, Zgaljardic, D., additional, Oden, K., additional, Lambert, M., additional, Dickson, S., additional, Miller, R., additional, Plenger, P., additional, Sutherland, E., additional, Glatts, C., additional, Schatz, P., additional, Walker, K., additional, Philip, N., additional, McClaughlin, S., additional, Mooney, S., additional, Seats, E., additional, Carnell, V., additional, Raintree, J., additional, Brown, D., additional, Hodges, C., additional, Amerson, E., additional, Kennedy, C., additional, Moore, J., additional, Ferris, C., additional, Roebuck-Spencer, T., additional, Vincent, A., additional, Bryan, C., additional, Catalano, D., additional, Warren, A., additional, Monden, K., additional, Driver, S., additional, Chau, P., additional, Seegmiller, R., additional, Baker, M., additional, Malach, S., additional, Mintz, J., additional, Villarreal, R., additional, Peterson, A., additional, Leininger, S., additional, Strong, C., additional, Donders, J., additional, Merritt, V., additional, Vargas, G., additional, Rabinowitz, A., additional, Arnett, P., additional, Whipple, E., additional, Schultheis, M., additional, Robinson, K., additional, Iacovone, D., additional, Biester, R., additional, Alfano, D., additional, Nicholls, M., additional, Klas, P., additional, Jeffay, E., additional, Zakzanis, K., additional, Vandermeer, M., additional, Womble, M., additional, Corley, E., additional, Considine, C., additional, Fichtenberg, N., additional, Harrison, J., additional, Pollock, M., additional, Mouanoutoua, A., additional, Brimager, A., additional, Lebby, P., additional, Sullivan, K., additional, Edmed, S., additional, Kieffer, K., additional, McCarthy, M., additional, Wiegand, L., additional, Lindsey, H., additional, Hernandez, M., additional, Noniyeva, Y., additional, Lapis, Y., additional, Padua, M., additional, Poole, J., additional, Brooks, B., additional, McKay, C., additional, Meeuwisse, W., additional, Emery, C., additional, Mazur-Mosiewicz, A., additional, Sherman, E., additional, Kirkwood, M., additional, Gunner, J., additional, Miele, A., additional, Silk-Eglit, G., additional, Lynch, J., additional, McCaffrey, R., additional, Stewart, J., additional, Tsou, J., additional, Scarisbrick, D., additional, Chan, R., additional, Bure-Reyes, A., additional, Cortes, L., additional, Gindy, S., additional, Biddle, C., additional, Shah, D., additional, Jaberg, P., additional, Moss, R., additional, Horner, M., additional, VanKirk, K., additional, Dismuke, C., additional, Turner, T., additional, Muzzy, W., additional, Dunnam, M., additional, Warner, G., additional, Donnelly, K., additional, Donnelly, J., additional, Kittleson, J., additional, Bradshaw, C., additional, Alt, M., additional, Margolis, S., additional, Ostroy, E., additional, Higgins, K., additional, Eng, K., additional, Akeson, S., additional, Wall, J., additional, Davis, J., additional, Hansel, J., additional, Wang, B., additional, Gervais, R., additional, Greiffenstein, M., additional, Denning, J., additional, VonDran, E., additional, Campbell, E., additional, Brockman, C., additional, Teichner, G., additional, Waid, R., additional, Buican, B., additional, Armistead-Jehle, P., additional, Bailie, J., additional, Dilay, A., additional, Cottingham, M., additional, Boyd, C., additional, Asmussen, S., additional, Neff, J., additional, Schalk, S., additional, Jensen, L., additional, DenBoer, J., additional, Hall, S., additional, Holcomb, E., additional, Axelrod, B., additional, Demakis, G., additional, Rimland, C., additional, Ward, J., additional, Ross, M., additional, Bailey, M., additional, Stubblefield, A., additional, Smigielski, J., additional, Geske, J., additional, Karpyak, V., additional, Reese, C., additional, Larrabee, G., additional, Allen, L., additional, Celinski, M., additional, Gilman, J., additional, LaDuke, C., additional, DeMatteo, D., additional, Heilbrun, K., additional, Swirsky-Sacchetti, T., additional, Dedman, A., additional, Withers, K., additional, Deneen, T., additional, Fisher, J., additional, Spray, B., additional, Savage, R., additional, Wiener, H., additional, Tyer, J., additional, Ningaonkar, V., additional, Devlin, B., additional, Go, R., additional, Sharma, V., additional, Fontanetta, R., additional, Calderon, C., additional, Coad, S., additional, Fontaneta, R., additional, Vertinski, M., additional, Verbiest, R., additional, Snyder, J., additional, Kinney, J., additional, Rach, A., additional, Young, J., additional, Crouse, E., additional, Schretlen, D., additional, Weaver, J., additional, Buchholz, A., additional, Gordon, B., additional, Macciocchi, S., additional, Seel, R., additional, Godsall, R., additional, Brotsky, J., additional, DiRocco, A., additional, Houghton-Faryna, E., additional, Bolinger, E., additional, Hollenbeck, C., additional, Hart, J., additional, Lee, B., additional, Strauss, G., additional, Adams, J., additional, Martins, D., additional, Catalano, L., additional, Waltz, J., additional, Gold, J., additional, Haas, G., additional, Brown, L., additional, Luther, J., additional, Goldstein, G., additional, Kelley, E., additional, Raba, C., additional, Trettin, L., additional, Solvason, H., additional, Buchanan, R., additional, Baldock, D., additional, Etherton, J., additional, Phelps, T., additional, Richmond, S., additional, Tapscott, B., additional, Thomlinson, S., additional, Cordeiro, L., additional, Wilkening, G., additional, Parikh, M., additional, Graham, L., additional, Grosch, M., additional, Hynan, L., additional, Weiner, M., additional, Cullum, C., additional, Menon, C., additional, Lacritz, L., additional, Castro-Couch, M., additional, Irani, F., additional, Houshyarnejad, A., additional, Norman, M., additional, Fonseca, F., additional, Browne, B., additional, Alvarez, J., additional, Jiminez, Y., additional, Baez, V., additional, Resendiz, C., additional, Scott, B., additional, Farias, G., additional, York, M., additional, Lozano, V., additional, Mahoney, M., additional, Hernandez Mejia, M., additional, Pacheco, E., additional, Homs, A., additional, Ownby, R., additional, Nici, J., additional, Hom, J., additional, Lutz, J., additional, Dean, R., additional, Finch, H., additional, Pierce, S., additional, Moses, J., additional, Mann, S., additional, Feinberg, J., additional, Choi, A., additional, Kaminetskaya, M., additional, Pierce, C., additional, Zacharewicz, M., additional, Gavett, B., additional, Horwitz, J., additional, Ory, J., additional, Carbuccia, K., additional, Morra, L., additional, Garcon, S., additional, Lucas, M., additional, Donovick, P., additional, Whearty, K., additional, Campbell, K., additional, Camlic, S., additional, Brinckman, D., additional, Ehrhart, L., additional, Weisser, V., additional, Medaglia, J., additional, Merzagora, A., additional, Reckess, G., additional, Ho, T., additional, Testa, S., additional, Woolery, H., additional, Farcello, C., additional, Klimas, N., additional, Meyer, J., additional, Barwick, F., additional, Drayer, K., additional, Galusha, J., additional, Schmitt, A., additional, Livingston, R., additional, Stewart, R., additional, Quarles, L., additional, Pagitt, M., additional, Barke, C., additional, Baker, A., additional, Baker, N., additional, Cook, N., additional, Ahern, D., additional, Correia, S., additional, Resnik, L., additional, Barnabe, K., additional, Gnepp, D., additional, Benjamin, M., additional, Zlatar, Z., additional, Garcia, A., additional, Harnish, S., additional, Crosson, B., additional, Vaughan, L., additional, Fedio, A., additional, Sexton, J., additional, Cummings, S., additional, Logemann, A., additional, Lassiter, N., additional, Fedio, P., additional, Gremillion, A., additional, Nemeth, D., additional, Whittington, T., additional, Reckow, J., additional, Lewandowski, C., additional, Cole, J., additional, Lewandowski, A., additional, Spector, J., additional, Ford-Johnson, L., additional, Lengenfelder, J., additional, Sumowski, J., additional, Morse, C., additional, McKeever, J., additional, Zhao, L., additional, Leist, T., additional, Marcinak, J., additional, Piecora, K., additional, Al-Khalil, K., additional, Martin, P., additional, Thompson, L., additional, Kowalczyk, W., additional, Golub, S., additional, Lemann, E., additional, Piehl, J., additional, Rita, N., additional, Moss, L., additional, Nogin, R., additional, Drapeau, C., additional, Malm, S., additional, Armstrong, L., additional, Glidewell, R., additional, Orr, W., additional, Mears, G., additional, Allen, C., additional, Pierson, E., additional, Kavanaugh, B., additional, Tayim, F., additional, Llanes, S., additional, Poston, K., additional, Beathard, J., additional, Stolberg, P., additional, Jones, W., additional, Mayfield, J., additional, Weller, J., additional, Demireva, P., additional, McInerney, K., additional, Riddle, T., additional, Primus, M., additional, Highsmith, J., additional, Everhart, D., additional, Lehockey, K., additional, Sullivan, S., additional, Mandava, S., additional, Murphy, B., additional, Lalwani, L., additional, Rosselli, M., additional, Carrasco, R., additional, Zuckerman, S., additional, Brand, J., additional, Rivera Mindt, M., additional, Schaffer, S., additional, Alper, K., additional, Devinsky, O., additional, Barr, W., additional, Langer, K., additional, Fraiman, J., additional, Scagliola, J., additional, Roman, E., additional, Martinez, A., additional, Konopacki, K., additional, Juliano, A., additional, Whiteside, D., additional, Widmann, G., additional, Franzwa, M., additional, Sokal, B., additional, Morgan, E., additional, Bondi, M., additional, Delano-Wood, L., additional, Cormier, R., additional, Cumley, N., additional, Elek, M., additional, Green, M., additional, Kruger, A., additional, Pacheco, L., additional, Robinson, G., additional, Welch, H., additional, Parriott, D., additional, Loe, S., additional, Hughes, L., additional, Natta, L., additional, Quenicka, W., additional, McGoldirck, K., additional, Bennett, T., additional, Soper, H., additional, Collier, S., additional, Connolly, M., additional, Di Pinto, M., additional, Handel, E., additional, Davidson, K., additional, Livers, E., additional, Frantz, S., additional, Allen, J., additional, Jerard, T., additional, Sakhai, S., additional, Barney, S., additional, McGoldrick, K., additional, Sordahl, J., additional, Torrence, N., additional, and John, S., additional
- Published
- 2012
- Full Text
- View/download PDF
4. Auditory Memory Decrements, Without Dissimulation, among Patients with Major Depressive Disorder
- Author
-
Considine, C. M., primary, Weisenbach, S. L., additional, Walker, S. J., additional, McFadden, E. M., additional, Franti, L. M., additional, Bieliauskas, L. A., additional, Maixner, D. F., additional, Giordani, B., additional, Berent, S., additional, and Langenecker, S. A., additional
- Published
- 2011
- Full Text
- View/download PDF
5. 198 IMPACT OF DEPRESSION ON STEPPING ACCURACY AMONG PATIENTS WITH HIGH FALL RISK
- Author
-
Wright, S., primary, Kay, R., additional, Avery, E., additional, Considine, C., additional, Bieliauskas, L., additional, Persad, C., additional, Giordani, B., additional, and Alexander, N., additional
- Published
- 2010
- Full Text
- View/download PDF
6. Uniaxial Stress Apparatus for Measurements of Optical Activity
- Author
-
Sample, H. H., primary, Considine, C. M., additional, and McCarthy, K. A., additional
- Published
- 1995
- Full Text
- View/download PDF
7. Broadband enhancement of light-matter interaction in 2D semiconductors by photonic hypercrystals.
- Author
-
Galfsky, T., Sun, Z., Considine, C. R., Lee, Y. H., Narimanov, E. E., and Menon, V. M.
- Published
- 2016
8. Reliability and validity of the Wolfram Unified Rating Scale (WURS)
- Author
-
Nguyen Chau, Foster Erin R, Paciorkowski Alexander R, Viehoever Amy, Considine Colleen, Bondurant Aidena, Marshall Bess A, and Hershey Tamara
- Subjects
Medicine - Abstract
Abstract Background Wolfram syndrome (WFS) is a rare, neurodegenerative disease that typically presents with childhood onset insulin dependent diabetes mellitus, followed by optic atrophy, diabetes insipidus, deafness, and neurological and psychiatric dysfunction. There is no cure for the disease, but recent advances in research have improved understanding of the disease course. Measuring disease severity and progression with reliable and validated tools is a prerequisite for clinical trials of any new intervention for neurodegenerative conditions. To this end, we developed the Wolfram Unified Rating Scale (WURS) to measure the severity and individual variability of WFS symptoms. The aim of this study is to develop and test the reliability and validity of the Wolfram Unified Rating Scale (WURS). Methods A rating scale of disease severity in WFS was developed by modifying a standardized assessment for another neurodegenerative condition (Batten disease). WFS experts scored the representativeness of WURS items for the disease. The WURS was administered to 13 individuals with WFS (6-25 years of age). Motor, balance, mood and quality of life were also evaluated with standard instruments. Inter-rater reliability, internal consistency reliability, concurrent, predictive and content validity of the WURS were calculated. Results The WURS had high inter-rater reliability (ICCs>.93), moderate to high internal consistency reliability (Cronbach’s α = 0.78-0.91) and demonstrated good concurrent and predictive validity. There were significant correlations between the WURS Physical Assessment and motor and balance tests (rs>.67, ps>.76, ps=-.86, p=.001). The WURS demonstrated acceptable content validity (Scale-Content Validity Index=0.83). Conclusions These preliminary findings demonstrate that the WURS has acceptable reliability and validity and captures individual differences in disease severity in children and young adults with WFS.
- Published
- 2012
- Full Text
- View/download PDF
9. Conductive Hydrogel Tapes for Tripolar EEG: A Promising Solution to Paste-Related Challenges.
- Author
-
Considine C and Besio W
- Subjects
- Humans, Adult, Male, Electric Conductivity, Female, Electric Impedance, Signal Processing, Computer-Assisted, Young Adult, Brain physiology, Electroencephalography methods, Hydrogels chemistry, Electrodes
- Abstract
Electroencephalography (EEG) remains pivotal in neuroscience for its non-invasive exploration of brain activity, yet traditional electrodes are plagued with artifacts and the application of conductive paste poses practical challenges. Tripolar concentric ring electrode (TCRE) sensors used for EEG (tEEG) attenuate artifacts automatically, improving the signal quality. Hydrogel tapes offer a promising alternative to conductive paste, providing mess-free application and reliable electrode-skin contact in locations without hair. Since the electrodes of the TCRE sensors are only 1.0 mm apart, the impedance of the skin-to-electrode impedance-matching medium is critical. This study evaluates four hydrogel tapes' efficacies in EEG electrode application, comparing impedance and alpha wave characteristics. Healthy adult participants underwent tEEG recordings using different tapes. The results highlight varying impedances and successful alpha wave detection despite increased tape-induced impedance. MATLAB's EEGLab facilitated signal processing. This study underscores hydrogel tapes' potential as a convenient and effective alternative to traditional paste, enriching tEEG research methodologies. Two of the conductive hydrogel tapes had significantly higher alpha wave power than the other tapes, but were never significantly lower.
- Published
- 2024
- Full Text
- View/download PDF
10. Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging.
- Author
-
Pierobon Mays G, Hett K, Eisma J, McKnight CD, Elenberger J, Song AK, Considine C, Richerson WT, Han C, Stark A, Claassen DO, and Donahue MJ
- Subjects
- Humans, Aged, Male, Female, Middle Aged, Motion, Parkinson Disease cerebrospinal fluid, Parkinson Disease diagnostic imaging, Parkinson Disease physiopathology, Diffusion Magnetic Resonance Imaging methods, Cerebrospinal Fluid diagnostic imaging, Cerebrospinal Fluid physiology
- Abstract
Background: Parkinson's disease is characterized by dopamine-responsive symptoms as well as aggregation of α-synuclein protofibrils. New diagnostic methods assess α-synuclein aggregation characteristics from cerebrospinal fluid (CSF) and recent pathophysiologic mechanisms suggest that CSF circulation disruptions may precipitate α-synuclein retention. Here, diffusion-weighted MRI with low-to-intermediate diffusion-weightings was applied to test the hypothesis that CSF motion is reduced in Parkinson's disease relative to healthy participants., Methods: Multi-shell diffusion weighted MRI (spatial resolution = 1.8 × 1.8 × 4.0 mm) with low-to-intermediate diffusion weightings (b-values = 0, 50, 100, 200, 300, 700, and 1000 s/mm
2 ) was applied over the approximate kinetic range of suprasellar cistern fluid motion at 3 Tesla in Parkinson's disease (n = 27; age = 66 ± 6.7 years) and non-Parkinson's control (n = 32; age = 68 ± 8.9 years) participants. Wilcoxon rank-sum tests were applied to test the primary hypothesis that the noise floor-corrected decay rate of CSF signal as a function of b-value, which reflects increasing fluid motion, is reduced within the suprasellar cistern of persons with versus without Parkinson's disease and inversely relates to choroid plexus activity assessed from perfusion-weighted MRI (significance-criteria: p < 0.05)., Results: Consistent with the primary hypothesis, CSF decay rates were higher in healthy (D = 0.00673 ± 0.00213 mm2 /s) relative to Parkinson's disease (D = 0.00517 ± 0.00110 mm2 /s) participants. This finding was preserved after controlling for age and sex and was observed in the posterior region of the suprasellar cistern (p < 0.001). An inverse correlation between choroid plexus perfusion and decay rate in the voxels within the suprasellar cistern (Spearman's-r=-0.312; p = 0.019) was observed., Conclusions: Multi-shell diffusion MRI was applied to identify reduced CSF motion at the level of the suprasellar cistern in adults with versus without Parkinson's disease; the strengths and limitations of this methodology are discussed in the context of the growing literature on CSF flow., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
11. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
- Author
-
Saloner R, Staffaroni A, Dammer E, Johnson ECB, Paolillo E, Wise A, Heuer H, Forsberg L, Lago AL, Webb J, Vogel J, Santillo A, Hansson O, Kramer J, Miller B, Li J, Loureiro J, Sivasankaran R, Worringer K, Seyfried N, Yokoyama J, Seeley W, Spina S, Grinberg L, VandeVrede L, Ljubenkov P, Bayram E, Bozoki A, Brushaber D, Considine C, Day G, Dickerson B, Domoto-Reilly K, Faber K, Galasko D, Geschwind D, Ghoshal N, Graff-Radford N, Hales C, Honig L, Hsiung GY, Huey E, Kornak J, Kremers W, Lapid M, Lee S, Litvan I, McMillan C, Mendez M, Miyagawa T, Pantelyat A, Pascual B, Paulson H, Petrucelli L, Pressman P, Ramos E, Rascovsky K, Roberson E, Savica R, Snyder A, Sullivan AC, Tartaglia C, Vandebergh M, Boeve B, Rosen H, Rojas J, Boxer A, and Casaletto K
- Abstract
The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations ( C9orf72, GRN, MAPT ) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN ) and extracellular matrix (particularly in MAPT ) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. 'Hub' proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets., Competing Interests: Competing Interests A.M.S. received research support from the NIA/NIH, the Bluefield Project to Cure FTD, and the Larry L. Hillblom Foundation. He has provided consultation to Alector, Lilly, Passage Bio, and Takeda. L.F. receives research support from the NIH. OH has received research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. J.S.Y. receives research support from the NIH. P.L. is a site primary investigator for clinical trials by Alector, AbbVie and Woolsey. He serves as an advisor for Retrotrope. He receives research and salary support from the NIH-NIA and the Alzheimer’s Association-Part the Cloud partnership. E.B. receives research support from the NIH and Lewy Body Dementia Association. B.C.D. is a consultant for Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Novartis, Takeda and Wave Lifesciences; receives royalties from Cambridge University Press, Elsevier and Oxford University Press; and receives grant funding from the NIA, the National Institute of Neurological Disorders and Stroke, the National Institute of Mental Health and the Bluefield Foundation. K.D.-R. receives research support from the NIH and serves as an investigator for a clinical trial sponsored by Lawson Health Research Institute. K.F. receives research support from the NIH. J.A.F. receives research support from the NIH. N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) and the A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial; and receives research support from Tau Consortium, the Association for Frontotemporal Dementia and the NIH. N.G.-R. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, TauRx, and Lilly; and receives research support from the NIH. C.M.H. is a Site PI or SubI for several industry (Alector, Janssen, Biogen, Cogito Tx) sponsored clinical trials with funding through Emory Office of Sponsored Programs. L.S.H. receives research funding from Abbvie, Acumen, Alector, Biogen, BMS, Eisai, Genentech/Roche, Janssen/J&J, Transposon, UCB, Vaccinex; and receives consulting fees from Biogen, Cortexyme, Eisai, Medscape, Prevail/Lilly. G.-Y.H. has served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly and Roche/Genentech; and he receives research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. E.D.H. receives research support from the NIH. J. Kornak has provided expert witness testimony for Teva Pharmaceuticals in Forest Laboratories Inc. et al. v. Teva Pharmaceuticals USA, Inc., case numbers 1:14-cv-00121 and 1:14-cv-00686 (D. Del. filed 31 January 2014 and 30 May 2014 regarding the drug Memantine) and for Apotex/HEC/Ezra in Novartis AG et al. v. Apotex Inc., case number 1:15-cv-975 (D. Del. filed 26 October 2015 regarding the drug Fingolimod); he has also given testimony on behalf of Puma Biotechnology in Hsingching Hsu et al, vs. Puma Biotechnology, Inc., et al. 2018 regarding the drug Neratinib; and he receives research support from the NIH. W.K. receives research funding from AstraZeneca, Biogen, Roche, the Department of Defense and the NIH. M.I.L. receives research support from the NIH. I.L.’s research is supported by the National Institutes of Health grants: 2R01AG038791–06A, U01NS100610, U01NS80818, R25NS098999; U19 AG063911–1 and 1R21NS114764–01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL - UCB. She is a Scientific advisor for Amydis and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology. C.T.M receives funding from NIH and Penn Institute on Aging. M.F.M. receives research support from the NIH. A.P. receives research support from the NIH (U01 NS102035; K23 AG059891). H.P. receives research support from the NIH. L.P. receives research support from the NIH. E.M.R. receives research support from the NIH. K.R. receives research support from the NIH. E.D.R. has received research support from the NIH, the Bluefield Project to Cure Frontotemporal Dementia, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, the BrightFocus Foundation, and Alector; has served as a consultant for AGTC and on a data monitoring committee for Lilly; and owns intellectual property related to tau and progranulin. R.S. receives support from the NIA, the National Institute of Neurological Disorders and Stroke, the Parkinson’s Disease Foundation and Acadia Pharmaceuticals. M.C.T. has served as an investigator for clinical trials sponsored by Biogen, Avanex, Green Valley, Roche/Genentech, Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals and Janssen. She receives research support from the Canadian Institutes of Health Research. B.F.B. has served as an investigator for clinical trials sponsored by Alector, Biogen, Transposon and Cognition Therapeutics. He serves on the Scientific Advisory Board of the Tau Consortium which is funded by the Rainwater Charitable Foundation. He receives research support from NIH. H.J.R. has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience, Ionis Pharmaceuticals, Eisai Pharmaceuticals, and Genentech, and receives research support from the NIH and the state of California. J.C.R. receives research support from the NIH and is a site principal investigator for clinical trials sponsored by Eli Lilly and Eisai. A.L.B. receives research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. He has served as a consultant for Aeovian, AGTC, Alector, Arkuda, Arvinas, Boehringer Ingelheim, Denali, GSK, Life Edit, Humana, Oligomerix, Oscotec, Roche, TrueBinding, Wave, Merck and received research support from Biogen, Eisai and Regeneron.
- Published
- 2024
- Full Text
- View/download PDF
12. Forensic neurology: a distinct subspecialty at the intersection of neurology, neuroscience and law.
- Author
-
Darby RR, Considine C, Weinstock R, and Darby WC
- Subjects
- Humans, Neurology, Mental Disorders
- Abstract
Neurological evidence is increasingly used in criminal cases to argue that a defendant is less responsible for their behaviour, is not competent to stand trial or should receive a reduced punishment for the crime. Unfortunately, neurologists are rarely involved in such cases despite having the expertise to help to inform these decisions in court. In this Perspective, we advocate for the development of 'forensic neurology', a subspecialty of neurology focused on using neurological clinical and scientific expertise to address legal questions for the criminal justice system. We review literature suggesting that the incidence of criminal behaviour is higher in people with certain neurological disorders than the general public and that undiagnosed neurological abnormalities are common in people who commit crimes. We discuss the need for forensic neurologists in criminal cases to provide an opinion on what neurological diagnoses are present, the resulting symptoms and ultimately whether the symptoms affect legal determinations such as criminal responsibility or competency., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
13. Deep learning segmentation of the choroid plexus from structural magnetic resonance imaging (MRI): validation and normative ranges across the adult lifespan.
- Author
-
Eisma JJ, McKnight CD, Hett K, Elenberger J, Han CJ, Song AK, Considine C, Claassen DO, and Donahue MJ
- Subjects
- Adult, Humans, Young Adult, Middle Aged, Aged, Aged, 80 and over, Image Processing, Computer-Assisted methods, Longevity, Choroid Plexus diagnostic imaging, Magnetic Resonance Imaging methods, Deep Learning
- Abstract
Background: The choroid plexus functions as the blood-cerebrospinal fluid (CSF) barrier, plays an important role in CSF production and circulation, and has gained increased attention in light of the recent elucidation of CSF circulation dysfunction in neurodegenerative conditions. However, methods for routinely quantifying choroid plexus volume are suboptimal and require technical improvements and validation. Here, we propose three deep learning models that can segment the choroid plexus from commonly-acquired anatomical MRI data and report performance metrics and changes across the adult lifespan., Methods: Fully convolutional neural networks were trained from 3D T
1 -weighted, 3D T2 -weighted, and 2D T2 -weighted FLAIR MRI using gold-standard manual segmentations in control and neurodegenerative participants across the lifespan (n = 50; age = 21-85 years). Dice coefficients, 95% Hausdorff distances, and area-under-curve (AUCs) were calculated for each model and compared to segmentations from FreeSurfer using two-tailed Wilcoxon tests (significance criteria: p < 0.05 after false discovery rate multiple comparisons correction). Metrics were regressed against lateral ventricular volume using generalized linear models to assess model performance for varying levels of atrophy. Finally, models were applied to an expanded cohort of adult controls (n = 98; age = 21-89 years) to provide an exemplar of choroid plexus volumetry values across the lifespan., Results: Deep learning results yielded Dice coefficient = 0.72, Hausdorff distance = 1.97 mm, AUC = 0.87 for T1 -weighted MRI, Dice coefficient = 0.72, Hausdorff distance = 2.22 mm, AUC = 0.87 for T2 -weighted MRI, and Dice coefficient = 0.74, Hausdorff distance = 1.69 mm, AUC = 0.87 for T2 -weighted FLAIR MRI; values did not differ significantly between MRI sequences and were statistically improved compared to current commercially-available algorithms (p < 0.001). The intraclass coefficients were 0.95, 0.95, and 0.96 between T1 -weighted and T2 -weighted FLAIR, T1 -weighted and T2 -weighted, and T2 -weighted and T2 -weighted FLAIR models, respectively. Mean lateral ventricle choroid plexus volume across all participants was 3.20 ± 1.4 cm3 ; a significant, positive relationship (R2 = 0.54-0.60) was observed between participant age and choroid plexus volume for all MRI sequences (p < 0.001)., Conclusions: Findings support comparable performance in choroid plexus delineation between standard, clinically available, non-contrasted anatomical MRI sequences. The software embedding the evaluated models is freely available online and should provide a useful tool for the growing number of studies that desire to quantitatively evaluate choroid plexus structure and function ( https://github.com/hettk/chp_seg )., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
14. Cerebrospinal Fluid Flow in Patients with Huntington's Disease.
- Author
-
Hett K, Eisma JJ, Hernandez AB, McKnight CD, Song A, Elenberger J, Considine C, Donahue MJ, and Claassen DO
- Subjects
- Adult, Humans, Cerebral Ventricles, Cerebral Aqueduct, Magnetic Resonance Imaging methods, Skull, Cerebrospinal Fluid, Huntington Disease diagnostic imaging, Huntington Disease cerebrospinal fluid
- Abstract
Objective: Investigations of cerebrospinal fluid (CSF) flow aberrations in Huntington's disease (HD) are of growing interest, as impaired CSF flow may contribute to mutant Huntington retention and observed heterogeneous responsiveness to intrathecally administered therapies., Method: We assessed net cerebral aqueduct CSF flow and velocity in 29 HD participants (17 premanifest and 12 manifest) and 51 age- and sex matched non-HD control participants using 3-Tesla magnetic resonance imaging methods. Regression models were applied to test hypotheses regarding: (i) net CSF flow and cohort, (ii) net CSF flow and disease severity (CAP-score), and (iii) CSF volume after correcting for age and sex., Results: Group-wise analyses support a decrease in net CSF flow in HD (mean 0.14 ± 0.27 mL/min) relative to control (mean 0.32 ± 0.20 mL/min) participants (p = 0.02), with lowest flow in the manifest HD cohort (mean 0.04 ± 0.25 mL/min). This finding was explained by hyperdynamic CSF movement, manifesting as higher caudal systolic CSF flow velocity and higher diastolic cranial CSF flow velocity across the cardiac cycle, in HD (caudal flow: 0.17 ± 0.07 mL/s, cranial flow: 0.14 ± 0.08 mL/s) compared to control (caudal flow: 0.13 ± 0.06 mL/s, cranial flow: 0.11 ± 0.04 mL/s) participants. A positive correlation between cranial diastolic flow and disease severity was observed (p = 0.02)., Interpretations: Findings support aqueductal CSF flow dynamics changing with disease severity in HD. These accelerated changes are consistent with changes observed over the typical adult lifespan, and may have relevance to mutant Huntington retention and intrathecally administered therapeutics responsiveness. ANN NEUROL 2023;94:885-894., (© 2023 American Neurological Association.)
- Published
- 2023
- Full Text
- View/download PDF
15. Deep learning segmentation of the choroid plexus from structural magnetic resonance imaging (MRI): validation and normative ranges across the adult lifespan.
- Author
-
Eisma JJ, McKnight CD, Hett K, Elenberger J, Song AK, Considine C, Claassen DO, and Donahue MJ
- Abstract
Background: The choroid plexus functions as the blood-cerebrospinal fluid barrier, plays an important role in neurofluid production and circulation, and has gained increased attention in light of the recent elucidation of neurofluid circulation dysfunction in neurodegenerative conditions. However, methods for routinely quantifying choroid plexus volume are suboptimal and require technical improvements and validation. Here, we propose three deep learning models that can segment the choroid plexus from commonly-acquired anatomical MRI data and report performance metrics and changes across the adult lifespan., Methods: Fully convolutional neural networks were trained from 3-D T
1 -weighted, 3-D T2 -weighted, and 2-D T2 -weighted FLAIR MRI and gold-standard manual segmentations in healthy and neurodegenerative participants across the lifespan (n=50; age=21-85 years). Dice coefficients, 95% Hausdorff distances, and area-under-curve (AUCs) were calculated for each model and compared to segmentations from FreeSurfer using two-tailed Wilcoxon tests (significance criteria: p<0.05 after false discovery rate multiple comparisons correction). Metrics were regressed against lateral ventricular volume using generalized linear models to assess model performance for varying levels of atrophy. Finally, models were applied to an expanded cohort of healthy adults (n=98; age=21-89 years) to provide an exemplar of choroid plexus volumetry values across the lifespan., Results: Deep learning results yielded Dice coefficient=0.72, Hausdorff distance=1.97 mm, AUC=0.87 for T1 -weighted MRI, Dice coefficient=0.72, Hausdorff distance=2.22 mm, AUC=0.87 for T2 -weighted MRI, and Dice coefficient=0.74, Hausdorff distance=1.69 mm, AUC=0.87 for T2 -weighted FLAIR MRI; values did not differ significantly between2 MRI sequences and were statistically improved compared to current commercially-available algorithms (p<0.001). The intraclass coefficients were 0.95, 0.95, and 0.96 between T1 -weighted and T2 -FLAIR, T1 -weighted and T2 -weighted, and T2 -weighted and T2 -FLAIR models, respectively. Mean lateral ventricle choroid plexus volume across all participants was 3.20±1.4 cm3 ; a significant, positive relationship (R2 =0.54; slope=0.047) was observed between participant age and choroid plexus volume for all MRI sequences (p<0.001)., Conclusions: Findings support comparable performance in choroid plexus delineation between standard, clinically available, non-contrasted anatomical MRI sequences. The software embedding the evaluated models is freely available online and should provide a useful tool for the growing number of studies that desire to quantitatively evaluate choroid plexus structure and function (https://github.com/hettk/chp_seg)., Competing Interests: Competing interests: No competing interests to declare.- Published
- 2023
- Full Text
- View/download PDF
16. Reduced suprasellar cistern cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with dynamic cycling of diffusion weightings.
- Author
-
Mays GP, Hett K, Eisma J, McKnight CD, Elenberger J, Song AK, Considine C, Han C, Stark A, Claassen DO, and Donahue MJ
- Abstract
Background: Parkinson's disease is characterized by dopamine-responsive symptoms as well as aggregation and accumulation of a-synuclein protofibrils. New diagnostic methods assess a-synuclein aggregation characteristics from cerebrospinal fluid and recent pathophysiologic mechanisms suggest that cerebrospinal fluid circulation disruptions may precipitate a-synuclein retention. Here, we test the hypothesis that cerebrospinal fluid motion at the level of the suprasellar cistern is reduced in Parkinson's disease relative to healthy participants and this reduction relates to choroid plexus perfusion., Methods: Diffusion weighted imaging (spatial resolution=1.8×1.8×4 mm) magnetic resonance imaging with cycling of diffusion weightings ( b -values=0, 50, 100, 200, 300, 700, and 1000 s/mm
2 ) over the approximate kinetic range of suprasellar cistern neurofluid motion was applied at 3-Tesla in Parkinson's disease (n=27; age=66±6.7 years) and healthy (n=32; age=68±8.9 years) participants. Wilcoxon rank-sum tests were applied to test the primary hypothesis that the decay rate of cerebrospinal fluid signal as a function of b -value, which reflects increasing fluid motion, is reduced in persons with versus without Parkinson's disease and inversely relates to choroid plexus activity assessed from perfusion-weighted magnetic resonance imaging (Spearman rank-order correlation; significance-criteria: p <0.05)., Results: Consistent with the primary hypothesis, decay rates were higher in healthy ( D =0.00328±0.00123mm2 /s) relative to Parkinson's disease ( D =0.00256±0.0094mm2 /s) participants ( p =0.016). This finding was preserved after controlling for age and sex. An inverse correlation between choroid plexus perfusion and decay rate ( p =0.011) was observed in Parkinson's disease participants., Conclusions: Cerebrospinal fluid motion at the level of the suprasellar cistern is often reduced in adults with versus without Parkinson's disease and this reduction correlates on average with choroid plexus perfusion.- Published
- 2023
- Full Text
- View/download PDF
17. Hyperactivity in patients with narcolepsy and idiopathic hypersomnia: an exploratory study.
- Author
-
Dodson C, Spruyt K, Considine C, Thompson E, Ipsiroglu OS, Bagai K, Silvestri R, Couvadelli B, and Walters AS
- Abstract
Introduction: Patients with either Idiopathic Hypersomnia or Narcolepsy demonstrate excessive daytime somnolence (EDS) with resultant inattention mimicking Attention Deficit Hyperactivity Disorder (ADHD). Patients with ADHD also often express sleep problems including EDS. Thus, patients with ADHD and patients with idiopathic hypersomnia or narcolepsy may share inattention and daytime drowsiness as common features. However, it is not known whether EDS patients with idiopathic hypersomnia or narcolepsy also have increased movement (hyperactivity) like ADHD patients, the determination of which is the purpose of this study., Methods: We studied 12 patients (7 Narcolepsy type 2 and 5 Idiopathic Hypersomnia) with EDS as shown by Multiple Sleep Latency Test which served as the gold standard for entry into the study. Twelve subjects without symptoms of EDS served as the control group. None of the participants had a previous history of ADHD. Each participant underwent a one-hour session laying at 45 degrees with surveys about the need to move and actigraphy as an objective measure of movement., Results: Sleep-disordered patients with EDS reported more symptoms of inattention and hyperactivity on the ADHD Self-Report Scale. At each of the time points patients with EDS had a clear trend to express the need to move more than controls on the Suggested Immobilization Test (SIT). For the total 60 minutes, a large effect size for the need to move during the SIT test was found between patients and controls (Cohen's d = 0.61, p=0.01). Patients with EDS did not express a need to move more to combat drowsiness than controls, nor did actigraphy show any difference in objective movement between patients and controls during the SIT., Conclusion: Patients with EDS express inattention and a need to move more than controls. However, hyperactivity was not verified by objective measurement, nor did the EDS patients express a need to move to combat drowsiness more than controls. Thus, a hypothesis to be further tested, is whether narcolepsy and idiopathic hypersomnia may be more a model of the inattentive form of ADHD rather than the combined or inattentive/hyperactive form of ADHD. Further studies are needed to explore the relationship between EDS and hyperactivity., Competing Interests: Competing interests: Arthur S. Walters M.D., Karen Spruyt Ph.D., Caroline Dodson B.S., Emily Thompson B.A., Kanika Bagai M.D., Rosali Silvestri M.D., Barbara Couvadelli M.D. PhD, Ciaran Considine PhD and Osman Ipsiroglu M.D. PhD have nothing to disclose.
- Published
- 2023
- Full Text
- View/download PDF
18. Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease.
- Author
-
McKnight CD, Trujillo P, Lopez AM, Petersen K, Considine C, Lin YC, Yan Y, Kang H, Donahue MJ, and Claassen DO
- Subjects
- Aged, Cognitive Dysfunction etiology, Cognitive Dysfunction physiopathology, Diffusion Tensor Imaging, Female, Humans, Male, Middle Aged, Severity of Illness Index, White Matter diagnostic imaging, White Matter pathology, Essential Tremor complications, Essential Tremor diagnostic imaging, Essential Tremor physiopathology, Glymphatic System diagnostic imaging, Glymphatic System physiopathology, Parkinson Disease complications, Parkinson Disease diagnostic imaging, Parkinson Disease physiopathology
- Abstract
Background: Reduced diffusion along perivascular spaces in adults with Alzheimer's-disease-related-dementias has been reported and attributed to reduced glymphatic function., Objectives: To apply quantitative measures of diffusion along, and orthogonal to, perivascular spaces in a cohort of older adults with and without clinical symptoms of alpha-synuclein related neurodegeneration., Methods: 181 adults with Parkinson disease (PD) or essential tremor (ET) additionally sub-classified by the presence of cognitive impairment underwent 3 T MRI. Diffusion-tensor-imaging (spatial resolution = 2x2x2 mm; b-value = 1000 s/mm
2 ; directions = 33) measures of diffusion (mm2 /s) parallel and orthogonal to perivascular spaces at the level of the medullary veins, and the ratio of these measures (ALPS-index), were calculated. Regions were identified by a board-certified neuroradiologist from T1 -weighted and T2 -weighted MRI. Evaluations of motor impairment and mild cognitive impairment (MCI) were interpreted by a board-certified neurologist and neuropsychologist, respectively. Multiple regression with false discovery rate correction was applied to understand how diffusion metrics related to (i) disease category (PD vs. ET), (ii) cognition (MCI status), and (iii) white matter disease severity from the Fazekas score., Results: The ALPS-index was reduced in PD compared to ET participants (p = 0.037). No association between the ALPS-index and MCI status, but an inverse association between the ALPS-index and Fazekas score (p = 0.002), was observed. The ALPS-index was inversely associated with age (p = 0.007)., Conclusion: Diffusion aberrations near perivascular spaces are evident in patients with alpha-synuclein related neurodegenerative disorders, and are related to age and white matter disease severity., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
19. Introducing the ImPACT-5: An Empirically Derived Multivariate Validity Composite.
- Author
-
Erdodi L, Korcsog K, Considine C, Casey J, Scoboria A, and Abeare C
- Subjects
- Humans, Male, Neuropsychological Tests, Reproducibility of Results, Sensitivity and Specificity, Brain Concussion, Football
- Abstract
Objective: To create novel Immediate Post-Concussion and Cognitive Testing (ImPACT)-based embedded validity indicators (EVIs) and to compare the classification accuracy to 4 existing EVIImPACT., Method: The ImPACT was administered to 82 male varsity football players during preseason baseline cognitive testing. The classification accuracy of existing EVIImPACT was compared with a newly developed index (ImPACT-5A and B). The ImPACT-5A represents the number of cutoffs failed on the 5 ImPACT composite scores at a liberal cutoff (0.85 specificity); ImPACT-5B is the sum of failures on conservative cutoffs (≥0.90 specificity)., Results: ImPACT-5A ≥1 was sensitive (0.81), but not specific (0.49) to invalid performance, consistent with EVIImPACT developed by independent researchers (0.68 sensitivity at 0.73-0.75 specificity). Conversely, ImPACT-5B ≥3 was highly specific (0.98), but insensitive (0.22), similar to Default EVIImPACT (0.04 sensitivity at 1.00 specificity). ImPACT-5A ≥3 or ImPACT-5B ≥2 met forensic standards of specificity (0.91-0.93) at 0.33 to 0.37 sensitivity. Also, the ImPACT-5s had the strongest linear relationship with clinically meaningful levels of invalid performance of existing EVIImPACT., Conclusions: The ImPACT-5s were superior to the standard EVIImPACT and comparable to existing aftermarket EVIImPACT, with the flexibility to optimize the detection model for either sensitivity or specificity. The wide range of ImPACT-5 cutoffs allows for a more nuanced clinical interpretation., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy.
- Author
-
Akers C, Acosta LMY, Considine C, Claassen D, Kirshner H, and Schrag M
- Subjects
- Aged, Alzheimer Disease complications, Alzheimer Disease diagnostic imaging, Cerebral Amyloid Angiopathy complications, Cerebral Hemorrhage etiology, Cognitive Dysfunction complications, Cognitive Dysfunction diagnostic imaging, Diagnosis, Differential, Female, Humans, Lewy Body Disease complications, Lewy Body Disease diagnostic imaging, Male, Brain diagnostic imaging, Cerebral Amyloid Angiopathy diagnostic imaging, Cerebral Hemorrhage diagnostic imaging, Neuroimaging methods
- Abstract
Purpose: Cerebral amyloid angiopathy is a vasculopathy caused by β-amyloid deposition in cerebral arterioles and capillaries. It is closely linked to Alzheimer's disease and predisposes elderly patients to intracerebral hemorrhage, transient focal neurological episodes, and cognitive impairment. Because of a predilection for symptomatic hemorrhage, particularly in the frontal lobes, cerebral amyloid angiopathy may also cause a dysexecutive syndrome., Recent Findings: In this case series, we describe presentations of classic clinical dementia syndromes which are not are widely thought to be associated with cerebral amyloid angiopathy, namely logopenic variant primary progressive aphasia (n = 3), normal pressure hydrocephalus (n = 3), and Lewy body dementia (n = 2). In every case, after a clinical diagnosis was established, neuroimaging, brain biopsy, and/or autopsy confirmed the presence of cerebral amyloid angiopathy. Cerebral amyloid angiopathy has significant clinical implications, and its ability to mimic and/or contribute to other clinical dementia syndromes can complicate its diagnosis. This series of cases broadens the range of clinical scenarios associated with cerebral amyloid angiopathy.
- Published
- 2019
- Full Text
- View/download PDF
21. Assembly of Excitatory Synapses in the Absence of Glutamatergic Neurotransmission.
- Author
-
Sando R, Bushong E, Zhu Y, Huang M, Considine C, Phan S, Ju S, Uytiepo M, Ellisman M, and Maximov A
- Subjects
- Animals, Dendrites physiology, Dendritic Spines physiology, Glutamic Acid metabolism, Mice, Neurogenesis physiology, Synapses physiology, Synaptic Transmission physiology, Excitatory Postsynaptic Potentials physiology, Hippocampus metabolism, Presynaptic Terminals metabolism, Synapses metabolism
- Abstract
Synaptic excitation mediates a broad spectrum of structural changes in neural circuits across the brain. Here, we examine the morphologies, wiring, and architectures of single synapses of projection neurons in the murine hippocampus that developed in virtually complete absence of vesicular glutamate release. While these neurons had smaller dendritic trees and/or formed fewer contacts in specific hippocampal subfields, their stereotyped connectivity was largely preserved. Furthermore, loss of release did not disrupt the morphogenesis of presynaptic terminals and dendritic spines, suggesting that glutamatergic neurotransmission is unnecessary for synapse assembly and maintenance. These results underscore the instructive role of intrinsic mechanisms in synapse formation., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
22. Traumatic unilateral vasomotor rhinitis.
- Author
-
Harlor EJ, Greene JS, and Considine C
- Subjects
- Accidents, Traffic, Cholinergic Antagonists therapeutic use, Female, Humans, Ipratropium therapeutic use, Rhinitis, Vasomotor drug therapy, Young Adult, Carotid Artery Injuries complications, Nasal Mucosa innervation, Rhinitis, Vasomotor etiology, Skull Fractures complications, Sympathetic Nervous System injuries
- Abstract
Vasomotor rhinitis (VMR) is a commonly encountered entity that may be difficult to diagnose. The classic symptoms are clear rhinorrhea and nasal congestion, commonly brought on by exercise, stress, heat, cold, and environmental irritants. The diagnosis is one of exclusion, and management usually involves avoidance of inciting agents and treatment with an anticholinergic nasal spray. We describe a case of VMR in a 22-year-old woman who presented with symptoms of clear, left-sided rhinorrhea and epiphora that had begun shortly after a motor vehicle accident approximately 1.5 years earlier, but which she had not reported at that time. The patient's left carotid canal had been fractured and the surrounding sympathetic plexus injured in the accident, resulting in an overactive parasympathetic system. Both exercise and heat exacerbated her symptoms. Allergy was excluded by negative allergy testing, and the patient did not respond to fluticasone nasal spray. Given the mechanism of injury, the unilaterality of symptoms, and the patient's lack of response to nasal steroids, it was thought that the VMR was due to the earlier traumatic injury, which had resulted in imbalance of the autonomic neural input. A trial of ipratropium was given to directly treat the parasympathetic overactivity. This treatment resulted in immediate improvement in both the nasal and lacrimal secretions.
- Published
- 2012
23. Pentoxifylline. Adjunctive therapy in the treatment of pedal frostbite.
- Author
-
Hayes DW Jr, Mandracchia VJ, Considine C, and Webb GE
- Subjects
- Acute Disease, Animals, Combined Modality Therapy, Foot pathology, Frostbite pathology, Frostbite physiopathology, Frostbite therapy, Hematologic Agents therapeutic use, Humans, Pentoxifylline pharmacology, Vasodilator Agents pharmacology, Frostbite drug therapy, Pentoxifylline therapeutic use, Vasodilator Agents therapeutic use
- Abstract
Frostbite injury to the extremities has the potential for disastrous effects. Prompt recognition and treatment are paramount. The use of Pentoxifylline to minimize tissue damage in the treatment of frostbite is a viable addition to the traditional therapy of rewarming soaks, pain management, and vesicle débridement. The most well known action of Pentoxifylline is its ability to increase RBC flexibility, allowing easier vascularization. This explains its indication for PVD, arterial disease, and intermittent claudication. As is explained previously, however, Pentoxifylline has multiple actions that will enhance tissue survival. The dosage of Pentoxifylline in controlled release tablet form is one 400 mg tablet three times a day with meals. The duration of treatment should be from two to six weeks. As this drug has many actions and therefore possibilities, more research is warranted with regards to its use not only with frostbite, but with other pathological processes.
- Published
- 2000
24. The private duty market: operational and staffing considerations.
- Author
-
Considine CJ
- Subjects
- Humans, Planning Techniques, Community Health Nursing organization & administration, Home Care Services organization & administration, Marketing of Health Services organization & administration, Nursing Staff organization & administration, Nursing, Private Duty organization & administration, Personnel Staffing and Scheduling organization & administration, Private Practice organization & administration
- Abstract
Wouldn't it be nice to get away from Medicare home health regulations and into a business where the provider simply needs an understanding of the difference between a revenue and an expense? Cost reports, disallowances, allocations, cost shifts, and cost limits become a thing of the past. This article will help you plan and evaluate your approach to developing a private duty business. An overview of the market, operational considerations, and a discussion of various key staff positions and their functions allows you to explore this opportunity from many vantage points.
- Published
- 2000
25. Measurement of outcomes: what does it really mean?
- Author
-
Considine CJ
- Subjects
- Humans, Patient Care Planning, United States, Centers for Medicare and Medicaid Services, U.S., Community Health Nursing standards, Home Care Services standards, Outcome Assessment, Health Care
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.